Esophageal Ulceration Related to Zalcitabine (ddC)
Authors: Amy S. Indorf, P. Samuel Pegram
Journal: Annals of Internal Medicine (1992)

Brief Report15 July 1992Esophageal Ulceration Related to Zalcitabine (ddC)Amy S. Indorf, MD, P. Samuel Pegram, MDAmy S. Indorf, MDSearch for more papers by this author, P. Samuel Pegram, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-117-2-133 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptZalcitabine (dideoxycytidine, ddC) is an antiretroviral agent whose efficacy in the management of human immunodeficiency virus (HIV) infection is currently being studied. We report a case of recurrent esophageal ulceration in a patient taking zalcitabine.Case ReportA 20-year-old white man with progressive HIV infection (CD4 lymphocyte count 50 cells/μL but no AIDS-defining illness) was enrolled in a randomized, double-blind study of zalcitabine compared with zidovudine on 7 June 1990. He had no history of esophageal or gastrointestinal disease before he entered the study. His only medications were clotrimazole troches and monthly aerosolized pentamidine. On 22 June the patient complained...References1. KikendallFriedmanOyewoleFleischerJohnson JAMDL. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci. 1983;28:174-82. CrossrefMedlineGoogle Scholar2. EdwardsTurnerGoldCooper PJJD. Esophageal ulceration induced by zidovudine. Ann Intern Med. 1990;112:65-6. LinkGoogle Scholar3. BachHowellValentiSmithWinslow MDATD. Aphthous ulceration of the gastrointestinal .tract in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1990;112:465-7. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From the Bowman Gray School of Medicine, Winston-Salem, North Carolina. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByMedication‐Induced Esophageal InjuryMedical Management of Swallowing DisordersDrug-Induced Esophageal InjuryPill-Induced Esophageal InjuryZalcitabineEsophagitisEsophageal Disorders Caused by Medications, Trauma, and InfectionStavudine, Didanosine, and ZalcitabineAntiretroviral Drugs to Treat Human Immunodeficiency Virus InfectionsDrug-Induced Esophageal Injuries and DysphagiaApproach to esophageal disease in AIDS: A primer for the endoscopistDiagnosis and Management of Infectious Esophagitis Associated with Human Immunodeficiency Virus InfectionPill esophagitisConsiderations in the Management of HIV Infection in Patients Undergoing Antineoplastic ChemotherapyMolecular mechanism of the short-term cardiotoxicity caused by 2′,3′-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactionsPill-Induced Esophagitis Caused by Oral RifampinIdiopathic Genital Ulcer Disease in an HIV-Infected WomanEsophageal Disease in Patients with AIDS: Diagnosis and TreatmentORAL AND ESOPHAGEAL DISORDERSIdiopathic Genital Ulcers in Women Infected with Human Immunodeficiency VirusAphthous vaginal ulceration in two women with acquired immunodeficiency syndromeZalcitabine-associated pharyngeal ulcersPamidronate: An unrecognized problem in gastrointestinal tolerabilityAIDS and the gutAn evaluation of oral ulcers in patients with AIDS and AIDS-related complexProgress in the understanding of HIV infection: An overviewZalcitabineZalcitabine and didanosineAntiviral drugsZalcitabine 15 July 1992Volume 117, Issue 2Page: 133-134KeywordsAntiretroviralsHIVHIV infectionsInfectious diseasesLymphocytesUlcers Issue Published: 15 July 1992 PDF DownloadLoading ...